Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

NCT00436007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

511

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: GSK 257049
BIOLOGICAL: Tritanrix™ HepB/Hib
BIOLOGICAL: Rouvax™
BIOLOGICAL: Stamaril™
BIOLOGICAL: Polio Sabin™

Sponsor

GlaxoSmithKline